Clinical Experience with Chemoradiotherapy Comprising S-1 Plus Low-dose Cisplatin in a Patient with Stage IV Anal Cancer
Overview
Authors
Affiliations
We report a case of anal cancer in a 58-year-old woman who complained of narrow, bloody stools and anal pain. Physical examination revealed anal stenosis associated with a circular mass arising in the anal canal. Histological examination of biopsy specimens confirmed a diagnosis of moderately differentiated squamous cell carcinoma. Enhanced computed tomography revealed anal cancer invading the levator ani and the vagina, with lymph-node, multiple hepatic, and pulmonary metastases. The patient received two cycle of chemoradiotherapy with S-1 plus low-dose cisplatin with rest for 4 weeks, leading to complete response of the primary lesion and a partial response of the metastatic lesions. Each cycle included oral S-1 (120 mg/body; day 1-21), cisplatin (10 mg/body; day 1-5, 8-12) and radiotherapy (2 Gy/day; day 1-5, 8-12, 15-19). Adverse effects of treatment were mild perineal skin erosion and mild appetite loss, but no hematologic toxicity. Although the patient died 16 months after first admission, chemoradiotherapy with S-1 plus cisplatin is potentially effective for the management of advanced anal cancer.
Funahashi K, Nemoto T, Koike J, Kurihara A, Shiokawa H, Ushigome M Surg Case Rep. 2016; 1(1):14.
PMID: 26943382 PMC: 4747969. DOI: 10.1186/s40792-015-0025-5.
Anal cancer treatment: current status and future perspectives.
Ghosn M, Kourie H, Abdayem P, Antoun J, Nasr D World J Gastroenterol. 2015; 21(8):2294-302.
PMID: 25741135 PMC: 4342904. DOI: 10.3748/wjg.v21.i8.2294.